Depressive DisordersNeuroimaging & Brain MeasuresKetamine

Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants

This review (2020) review looks at the common mechanisms that underly the effects of ketamine and classical psychedelics. Although the research is in its infancy, the authors identify neuroplasticity via glutamatergic common downstream mechanisms.

Authors

  • Carlos Zarate
  • Lawrence Park

Published

International Journal of Neuropsychopharmacology
meta Study

Abstract

Background

The glutamatergic modulator ketamine has created a blueprint for studying novel pharmaceuticals in the field. Recent studies suggest that “classic” serotonergic psychedelics (SPs) may also have antidepressant efficacy. Both ketamine and SPs appear to produce rapid, sustained antidepressant effects after a transient psychoactive period.

Methods

This review summarizes areas of overlap between SP and ketamine research and considers the possibility of a common, downstream mechanism of action. The therapeutic relevance of the psychoactive state, overlapping cellular and molecular effects, and overlapping electrophysiological and neuroimaging observations are all reviewed.

Results

Taken together, the evidence suggests a potentially shared mechanism wherein both ketamine and SPs may engender rapid neuroplastic effects in a glutamatergic activity-dependent manner. It is postulated that, though distinct, both ketamine and SPs appear to produce acute alterations in cortical network activity that may initially produce psychoactive effects and later produce milder, sustained changes in network efficiency associated with therapeutic response. However, despite some commonalities between the psychoactive component of these pharmacologically distinct therapies-such as engagement of the downstream glutamatergic pathway-the connection between psychoactive impact and antidepressant efficacy remains unclear and requires more rigorous research.

Conclusions

Rapid-acting antidepressants currently under investigation may share some downstream pharmacological effects, suggesting that their antidepressant effects may come about via related mechanisms. Given the prototypic nature of ketamine research and recent progress in this area, this platform could be used to investigate entirely new classes of antidepressants with rapid and robust actions.

Available with Blossom Pro

Research Summary of 'Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants'

Introduction

Kadriu and colleagues situate their review in the context of a paradigm shift in antidepressant pharmacotherapy triggered by subanesthetic ketamine, which produces rapid and relatively sustained antidepressant effects contrary to the long lag time typical of conventional monoaminergic treatments. They note that ketamine has provided a clinical and methodological blueprint for evaluating other compounds with abuse liability and that recent clinical studies suggest classic serotonergic psychedelics (SPs) such as psilocybin, LSD, ayahuasca (DMT), and 5-MeO-DMT may also produce rapid, durable reductions in depressive symptoms following a transient psychoactive period. This paper aims to summarise areas of overlap between ketamine and SP research rather than provide an exhaustive clinical review. Specifically, the authors review converging cellular and molecular mechanisms, electrophysiological and neuroimaging observations, and the therapeutic relevance of the psychoactive state, and they consider whether a common downstream, glutamate-dependent mechanism could underlie rapid-acting antidepressant (RAAD) effects across these pharmacologically distinct agents. They emphasise that modern SP research remains preliminary and that rigorous investigation is required to clarify safety, efficacy, and mechanisms.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (55)

Papers cited by this study that are also in Blossom

Ketamine Treatment and Global Brain Connectivity in Major Depression

Abdallah, C. G., Averill, L. A., Collins, K. A. et al. · Neuropsychopharmacology (2016)

292 cited
Classic hallucinogens and mystical experiences: phenomenology and neural correlates

Barrett, F. S., Griffiths, R. R. · Current Topics in Behavioral Neurosciences (2017)

Antidepressant effects of ketamine in depressed patients

Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)

Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression

Cameron, L. P., Benson, C. J., Dunlap, L. E. · ACS Chemical Neuroscience (2018)

The therapeutic potential of psychedelic drugs: past, present, and future

Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)

Show all 55 references
Neural correlates of the LSD experience revealed by multimodal neuroimaging

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)

Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial

Galvão-Coelho, N. L., de Almeida, R. N., de Menezes Galvão, A. C. et al. · Frontiers in Psychology (2019)

Psychedelics as anti-inflammatory agents

Flanagan, T. W., Nichols, C. D. · International Review of Psychiatry (2018)

Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca

Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N. et al. · Journal of Psychopharmacology (2020)

84 cited
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)

594 cited
Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior

Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)

818 cited
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Ketamine-induced modulation of the thalamo-cortical network in healthy volunteers as a model for schizophrenia

Höflich, A., Hahn, A., Küblböck, M. et al. · International Journal of Neuropsychopharmacology (2015)

109 cited
Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.

Holze, F., Vizeli, P., Müller, F. et al. · Neuropsychopharmacology (2019)

214 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)

The hidden therapist: evidence for a central role of music in psychedelic therapy

Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)

213 cited
Administration of ketamine for unipolar and bipolar depression

Kraus, C., Rabl, U., Vanicek, T. et al. · International Journal of Psychiatry in Clinical Practice (2017)

Psychedelic Drugs in Biomedicine

Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R. et al. · Trends in Pharmacological Sciences (2017)

Psychedelics promote structural and functional neural plasticity

Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)

The Effects of Hallucinogens on Gene Expression

Martin, D. A., Nichols, C. D., Nichols, Á. C. D. · Current Topics in Behavioral Neurosciences (2017)

Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin

Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)

New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)

Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression

Murrough, J. W., Perez, A. M., Pillemer, S. et al. · Biological Psychiatry (2012)

Broadband Cortical Desynchronization Underlies the Human Psychedelic State

Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)

427 cited
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report

Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)

420 cited
The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network

Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)

Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives

Pallavicini, C., Vilas, M. G., Villarreal, M. et al. · NeuroImage (2019)

51 cited
Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression

Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)

Psychiatry & the psychedelic drugs. Past, present & future

Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression a SPECT study

Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)

380 cited
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin

Schartner, M., Carhart-Harris, R. L., Barrett, A. B. et al. · Scientific Reports (2017)

19 cited
Acute Biphasic Effects of Ayahuasca

Schenberg, E. E., Alexandre, J. F. M., Filev, R. et al. · PLOS ONE (2015)

101 cited
Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans

Valle, M., Maqueda, A. E., Rabella, M. et al. · European Neuropsychopharmacology (2016)

145 cited
Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the Clinician Administered Dissociative State Scale

Van Schalkwyk, G. I., Wilkinson, S. T., Davidson, L. et al. · Journal of Affective Disorders (2018)

65 cited
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)

Mechanisms of ketamine action as an antidepressant

Zanos, P., Gould, T. D. · Molecular Psychiatry (2018)

Replication of Ketamine’s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

Zarate, C. A., Brutsche, N. E., Ibrahim, L. et al. · Biological Psychiatry (2012)

757 cited

Cited By (13)

Papers in Blossom that reference this study

The psychoplastogen tabernanthalog induces neuroplasticity without proximate immediate early gene activation

Aarrestad, I. K., Cameron, L. P., Fenton, E. M. et al. · Nature Neuroscience (2025)

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome

Dahan, J. D. C., Dadiomov, D., Bostoen, T. et al. · npj Mental Health Research (2024)

Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response

Calder, A. E., Rausch, B., Liechti, M. E. et al. · Journal of Psychopharmacology (2024)

5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines

Cameron, L. P., Patel, S. D., Vargas, M. V. et al. · ACS Chemical Neuroscience (2023)

86 cited
Psychedelic-Assisted Therapy for People with Eating Disorders

Gukasyan, N., Schreyer, C. C., Griffiths, R. R. et al. · Current Psychiatry Reports (2022)

21 cited
Beating Pain with Psychedelics: Matter over Mind?

Elman, I., Borsook, D., Pustilink, A. · Neuroscience and Biobehavioral Reviews (2022)

Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)

Show all 13 papers
Serotonergic Psychedelics in Neural Plasticity

Torregrossa, M. M., Lu, J., Lukasiewicz, K. et al. · Frontiers in Molecular Neuroscience (2021)

Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy

Yehuda, R., Lepow, L., Morishita, H. · Frontiers in Neuroscience (2021)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.